Barclays PLC Icosavax, Inc. Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$5.95 - $15.79 $978,221 - $2.6 Million	-164,407 Reduced 81.32%	37,775 $595,000
Q3 2023 Nov 07, 2023	BUY	$7.22 - $10.05 $1.42 Million - $1.98 Million	196,702 Added 3589.45%	202,182 $1.57 Million
Q2 2023 Aug 03, 2023	SELL	$4.89 - $10.57 $37,217 - $80,448	-7,611 Reduced 58.14%	5,480 $55,000
Q1 2023 May 04, 2023	BUY	$5.62 - $11.51 $39,739 - $81,387	7,071 Added 117.46%	13,091 $75,000
Q4 2022 Feb 13, 2023	BUY	$2.32 - $10.97 $11,660 - $55,135	5,026 Added 505.63%	6,020 $47,000
Q3 2022 Nov 03, 2022	SELL	$3.09 - $9.21 $31,709 - $94,513	-10,262 Reduced 91.17%	994 $3,000
Q2 2022 Aug 12, 2022	BUY	$5.7 - $10.33 $41,461 - $75,140	7,274 Added 182.67%	11,256 $64,000
Q1 2022 May 16, 2022	BUY	$4.41 - $22.5 $17,560 - $89,595	3,982 New	3,982 $28,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.